Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anesthesia combo may speed recovery after day surgery

NCT ID NCT07663877

Symptom relief Sponsor: Chung-Ang University Gwangmyeong Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a short-acting sedative (remimazolam) followed by a reversal drug (flumazenil) can help women wake up faster after hysteroscopic day surgery compared to standard anesthesia. About 124 adult women will be randomly assigned to one of the two methods. The main goal is to see if the new approach shortens the time from starting anesthesia to being ready for discharge, while keeping recovery safe and comfortable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remimazolam (a short-acting sedative) and flumazenil (a reversal agent)
What this could lead to
If successful, this approach could help patients wake up faster after day surgery and allow hospitals to run more efficiently.
What could go wrong
This is a small, early-phase trial (124 participants) comparing two anesthesia methods, not testing a new treatment. The results may not apply to other surgeries or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 20 years or older. * Scheduled to undergo ambulatory hysteroscopic surgery under general anesthesia. * Able to provide written informed consent. * American Society of Anesthesiologists (ASA) physical status I-III. Exclusion Criteria: * Known hypersensitivity to benzodiazepines, remimazolam, or flumazenil. * Chronic use of benzodiazepines or opioids. * Severe hepatic dysfunction (Child-Pugh class B or C). * Severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m²). * Epilepsy or other significant neurologic disorders. * Pregnancy or breastfeeding. * Body mass index (BMI) ≥35 kg/m². * Severe obstructive sleep apnea. * Uncontrolled serious systemic disease that may preclude ambulatory surgery. * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ambulatory surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ambulatory surgery General anesthesia Hysteroscopy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, Gyeonggi-do, 14353, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.